Emendobio Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Novel CRISPR Nuclease (US 11,666,641) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Compositions for Genome Editing (US 11,795,453) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Differential Knockout of an Allele of a Heterozygous Bestrophin 1 Gene (US 11,827,879) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Novel OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR Nucleases (US 11,946,077) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,612,625 | Compositions for Genome Editing In force · High confidence | In force | High confidence | |
| US 12,168,062 | Guide RNA That Targets a Mutant Human Guanylate Cyclase 2A Allele In force · High confidence | In force | High confidence | |
| US 12,274,758 | Guide RNA That Targets a Mutant Human Inosine Monophosphate Deyhydrogenase I Allele In force · High confidence | In force | High confidence | |
| US 11,274,288 | Compositions and Methods for Promoting Homology Directed Repair Mediated Gene Editing In force · High confidence | In force | High confidence | |
| US 11,795,453 | Compositions for Genome Editing In force · High confidence | In force | High confidence | |
| US 11,666,641 | Novel CRISPR Nuclease In force · High confidence | In force | High confidence | |
| US 12,359,196 | Differential Knockout of an Allele of a Heterozygous Fibrinogen Alpha Chain (FGA) Gene In force · High confidence | In force | High confidence | |
| US 11,946,077 | Novel OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR Nucleases In force · High confidence | In force | High confidence | |
| US 11,827,879 | Differential Knockout of an Allele of a Heterozygous Bestrophin 1 Gene In force · High confidence | In force | High confidence | |
| US 12,480,140 | Differential Knockout of an Allele of a Heterozygous Elane Gene In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
27 pending · 9 abandoned